Meisa Propst

Meisa has over 22 years of experience in both pre-clinical and clinical research in oncology, hematology, CNS, neurology, cardiovascular, and transfusion medicine. Before joining InCarda, Meisa most recently served as the Head of Clinical Operations at Sunesis Pharmaceuticals where she oversaw clinical development and functional resourcing planning for the development pipeline. Previously, Meisa supported BioMarin’s oncology and neurology pipeline where she was instrumental in the transfer of the PARPi molecule, talazoparib, during its acquisition and the launch of a compassionate use program for Duchenne Muscular Dystrophy. From 2004 to 2014, Meisa had increasing responsibilities within Clinical Operations at Novacea, Bavarian Nordic, and Cerus Corporation.